Pre-clinical studies indicate synergy between RT and TAX in astrocytoma cell lines. 3 or 4 neutropenia or thrombocytopenia. Median potential follow-up time is 20 mos. Median survival is 9.7 mos with median survivals for RPA classes III, IV, V, and VI 16.3, 10.2, 9.5, 2.5 mos respectively. 10 pts remain alive.
TAX is feasible in the majority of GBM patients.